List of Excipients in API ritlecitinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ritlecitinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | CELLULOSE, MICROCRYSTALLINE | 2028-06-23 |
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | CROSPOVIDONE | 2028-06-23 |
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | FD&C BLUE NO. 1 | 2028-06-23 |
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | FERRIC OXIDE YELLOW | 2028-06-23 |
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | GLYCERYL DIBEHENATE | 2028-06-23 |
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | HYPROMELLOSE | 2028-06-23 |
| Pfizer Laboratories Div Pfizer Inc | LITFULO | ritlecitinib | 0069-0334 | LACTOSE MONOHYDRATE | 2028-06-23 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ritlecitinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ritlecitinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
ritlecitinib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
ritlecitinib drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ritlecitinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL DIBEHENATE
ritlecitinib drug variants containing GLYCERYL DIBEHENATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing GLYCERYL DIBEHENATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
ritlecitinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
ritlecitinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ritlecitinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | ritlecitinib | 0069-0334 |
| US Pharmaceuticals | ritlecitinib | 63539-334 |
| >Company | >Ingredient | >NDC |
ritlecitinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
